Extended-release metformin improves cognitive impairment in frail older women with hypertension and diabetes: preliminary results from the LEOPARDESS Study

Pasquale Mone, Giuseppe Martinelli, Angela Lucariello, Anna Luisa Leo, Anna Marro, Stefano De Gennaro, Stefania Marzocco, Divina Moriello, Salvatore Frullone, Luigi Cobellis, Gaetano Santulli

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

Background: Women have a high risk of frailty independently of age and menopause state. Diabetes and hypertension increase the risk of frailty and cognitive impairment. Metformin has been employed in post-menopausal women and some reports have shown encouraging effects in terms of attenuated frailty. However, the impact on cognitive performance of a recently introduced extended-release formulation of metformin has never been explored. Methods: We studied consecutive frail hypertensive and diabetic older women presenting at the ASL (local health authority of the Italian Ministry of Health) Avellino, Italy, from June 2021 to August 2022, who were treated or not with extended-release metformin. We included a control group of frail older males with diabetes and hypertension treated with extended-release metformin and a control group of frail older women with diabetes and hypertension treated with regular metformin. Results: A total of 145 patients successfully completed the study. At the end of the 6-month follow-up, we observed a significantly different cognitive performance compared to baseline in the group of frail women treated with extended-release metformin (p: 0.007). Then, we compared the follow-up groups and we observed significant differences between frail women treated vs. untreated (p: 0.041), between treated frail women and treated frail men (p: 0.016), and between women treated with extended-release metformin vs. women treated with regular metformin (p: 0.048). We confirmed the crucial role of extended-release metformin applying a multivariable logistic analysis to adjust for potential confounders. Conclusions: We evidenced, for the first time to the best of our knowledge, the favorable effects on cognitive impairment of extended-release metformin in frail women with diabetes and hypertension.

Original languageEnglish (US)
Article number94
JournalCardiovascular Diabetology
Volume22
Issue number1
DOIs
StatePublished - Dec 2023

Keywords

  • Aging
  • Biguanides
  • Cognitive dysfunction
  • Frailty
  • Hyperglycemia
  • Menopause
  • Metformin
  • Sex differences
  • Women’s health

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Extended-release metformin improves cognitive impairment in frail older women with hypertension and diabetes: preliminary results from the LEOPARDESS Study'. Together they form a unique fingerprint.

Cite this